$200 Blood Test Spots Diabetes & Heart Risk
Epigenetic Biomarker Predicts Cardiovascular Event Risk in Newly Diagnosed type 2 Diabetes
Table of Contents
Type 2 diabetes (T2D) dramatically increases teh risk of major adverse cardiovascular events (MACE), including myocardial infarction (MI) and stroke. While clinical risk factors are used to assess this risk, they frequently enough lack the precision needed for targeted preventative strategies. Recent research has identified a novel blood-based epigenetic biomarker, the Methylation Risk Score (MRS), that significantly improves prediction of incident major events (iMEs) in individuals newly diagnosed with T2D, offering a potential new tool for personalized cardiovascular risk assessment.
Identifying and Validating the Methylation Risk Score
Researchers developed the MRS by analyzing DNA methylation patterns – chemical modifications to DNA that don’t alter the sequence but can influence gene expression – in blood samples. The initial MRS, comprised of 87 methylation sites across 64 genes, demonstrated superior predictive power compared to traditional risk scores. Specifically, the MRS outperformed the UKPDS and SCORE2-Diabetes risk scores (AUCs of 0.54 and 0.62, respectively) in predicting iMEs. it also showed better performance than polygenic risk scores (PRS) and other established cardiovascular risk assessments like the multi-ethnic study of atherosclerosis, atherosclerotic CVD, and Framingham risk scores (AUCs ranging from 0.61 to 0.68).
The optimal cutoff point for the combined biomarker tool, utilizing MRS alongside clinical factors, was determined to be 0.023. At this threshold, the model achieved a sensitivity of 80.4% and a specificity of 72.8%, indicating a strong ability to identify individuals unlikely to experience iMEs (negative predictive value of 95.9%).While positive predictive value was more moderate (31.8%), the model demonstrated a substantial improvement in risk classification. Net reclassification improvement analyses revealed a 28.2% categorical and 90.2% continuous improvement over clinical risk factors alone.
Further examination revealed that many of the genes identified within the MRS have established links to cardiovascular disease,with 72% having prior associations in the scientific literature or genome-wide association studies (GWAS). Importantly, methylation patterns at several sites overlapped with those observed in aortic plaque tissue, suggesting a direct biological connection to the disease process.
Refining and Validating the MRS: The MRS5sites Model
To simplify the biomarker and potentially reduce costs, researchers further refined the MRS to a five-site model (MRS5sites). This streamlined version maintained significant discriminatory power, demonstrating differences between control groups and individuals with iMEs in the OPTIMED cohort and a prospective cohort of individuals with T2D.
Combining clinical risk factors with the MRS5sites yielded an impressive area under the curve (AUC) of 0.8 in the OPTIMED cohort and 0.78 in the prospective T2D cohort. The OPTIMED cohort included individuals newly diagnosed with T2D, while the EPIC-Potsdam cohort represented a general population, bolstering the broader applicability of the findings.
Clinical Implications and Future Directions
This study establishes a promising epigenetic biomarker for predicting cardiovascular risk in individuals newly diagnosed with T2D. A combined MRS (or MRS5sites) score exceeding 0.023 suggests a heightened risk of developing iMEs within a seven-year follow-up period. The estimated cost of approximately $200 per sample, while not insignificant, could be feasible for targeted screening in high-risk populations.
However, several considerations remain. The authors emphasize the need for external validation in diverse ethnicities to confirm the generalizability of the findings.The moderate positive predictive value is likely influenced by the relatively low event rate in the newly diagnosed T2D population studied. Furthermore, the impact of lifestyle factors – diet, physical activity, and medication – on DNA methylation patterns, which were not fully accounted for in the current cohorts, warrants further investigation.
Future research should focus on incorporating these environmental factors into risk models and exploring the potential for epigenetic-targeted therapies to mitigate cardiovascular risk in individuals with T2D. The MRS represents a significant step towards personalized cardiovascular risk assessment and preventative care in this vulnerable population.